Clavis Pharmaceuticals shares flat-lined at about 18 cents this morning as the Norwegian biotech company outlined a simple endgame after its second Phase III cancer drug program ended in failure yesterday. CEO Olav Hellebo told reporters today...
The former proprietary drug business of Abbott Laboratories (ABT), now split off into AbbVie (ABBV), expects to continue to benefit from the robust growth of its Humira biologic for myriad autoimmune diseases.
A two-year research project aims to crack the lignin question by engineering a microbe to break down the byproduct into a lipid, or fat, and then into biodiesel. The research has the potential to make cellulosic biorefineries more profitable.
April Flowers for redOrbit.com - Your Universe Online
Scientists have discovered a hearing system component previously thought to be unique to toothed whales – such as dolphins – in insects.
The team, comprised of scientists from the...
LOS ANGELES (MedPage Today) -- Day two at the American Heart Association meeting featured the latest findings from researchers for the Physicians' Health Study II and promising, but very early results, from a study of an investigational...
(MedPage Today) -- Americans have seen the enemy -- LDL cholesterol -- and are beating it into submission. Moreover, they appear to be winning the battle with a combination of good diet, good medicine, and good living.
(MedPage Today) -- Moderately obese patients who participated in a 2-year diet intervention were able to maintain at least some weight loss and a lower lipid profile through 6 years, researchers found.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.